New Medication for Osteoarthritis Knee Pain

Trial Objective

New Medication for Osteoarthritis Knee PainThe purpose of this trial is to determine if a new FDA-approved medication called  Hymovis™ is effective in reducing or eliminating pain in people with osteoarthritis in their knee. The medication will be injected into the participant’s knee using a pneumatic  external compression device called KneeTap™ guided by ultrasound. This study will determine how the knee joint fluid proteins react to this medication to help reduce cartilage loss and joint pain.


New enrollment for this trial is temporarily paused

Who Can Participate

Patients who have an x-ray confirming mild to moderate osteoarthritis in the knee. Participants must not have had a knee infection or knee surgery within 12 months or a cortisone injection within 3 months of starting the study. Participants must be able to walk six minutes without a cane or walker.

Age: 21-80    Gender: Any Gender

Estimated Time Commitment

5 visits over 12 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Mary Gill

Mary Gill

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Principal Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More